Mesenchymal Stem Cell Based Approaches for Systemic Lupus Erythematosus Immunotherapy

  • Xuexiao JinEmail author
  • Shen Lu
  • Yang Yao
Part of the Stem Cells in Clinical Applications book series (SCCA)


Systemic lupus erythematosus (SLE) is an autoimmune disease, which is characterized by multi-organ involvement, with significant morbidity and mortality in young women predominantly. SLE is pathologically characterized by self-activation of auto-reactive immune responses, including activation of auto-reactive T cells and overproduction of autoantibodies by B cells. Although corticosteroids and immune-suppressants are widely used for the treatment, safer and more effective therapies are needed. The immunomodulatory properties and low immunogenic potential of mesenchymal stem cells (MSCs) make them a very promising new choice for treatment of severe refractory SLE. In this chapter, we provide a brief overview of MSCs treatment in SLE and describe current knowledge of the mechanisms by which they play parts in treating the disease, for better understanding of the pathogenesis and therapy for SLE.


Mesenchymal stem cell Systemic lupus erythematosus Autoimmunity Immunotherapy Immunosuppression 



Antigen-presenting cells


B7 homolog 1


B cell activating factor


Bone marrow


Regulatory B cells


Dendritic cells


Hepatocyte growth factor


Hematopoietic stem cells




Interferon gamma


Mycophenolate mofetil


Mesenchymal stem cells

NK cells

Natural killer cells


Nitric oxide


Non-steroidal anti-inflammatory drugs


Prostaglandin E2


Systemic lupus erythematosus


Systemic lupus erythematosus disease activity index


Transforming growth factor-β

TH cells

T helper cells


Tumor necrosis factor alpha


Regulatory T cells


Umbilical cord


  1. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822CrossRefGoogle Scholar
  2. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533CrossRefGoogle Scholar
  3. Bernard M, Dieude M, Yang B, Hamelin K, Underwood K, Hebert MJ (2014) Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. Autophagy 10:2193–2207CrossRefGoogle Scholar
  4. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557CrossRefGoogle Scholar
  5. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540–1543CrossRefGoogle Scholar
  6. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D (2010) IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5:e14247CrossRefGoogle Scholar
  7. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, Villa Bs M, Takahashi M, Jovanovic B, Oyama Y (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295:527–535CrossRefGoogle Scholar
  8. Chang JW, Hung SP, Wu HH, Wu WM, Yang AH, Tsai HL, Yang LY, Lee OK (2011) Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant 20:245–257CrossRefGoogle Scholar
  9. Choi EW, Shin IS, Park SY, Park JH, Kim JS, Yoon EJ, Kang SK, Ra JC, Hong SH (2012) Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 64:243–253CrossRefGoogle Scholar
  10. Crispin JC, Tsokos GC (2010) Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 22:499–503CrossRefGoogle Scholar
  11. Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318CrossRefGoogle Scholar
  12. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999–3001CrossRefGoogle Scholar
  13. Fan L, Hu C, Chen J, Cen P, Wang J, Li L (2016) Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci 17CrossRefGoogle Scholar
  14. Figueroa FE, Cuenca Moreno J, La Cava A (2014) Novel approaches to lupus drug discovery using stem cell therapy. Role of mesenchymal-stem-cell-secreted factors. Expert Opin Drug Discov 9:555–566CrossRefGoogle Scholar
  15. Francois M, Romieu-Mourez R, Li M, Galipeau J (2012) Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187–195CrossRefGoogle Scholar
  16. Gatto M, Zen M, Ghirardello A, Bettio S, Bassi N, Iaccarino L, Punzi L, Doria A (2013) Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 12:523–536CrossRefGoogle Scholar
  17. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60:1006–1019CrossRefGoogle Scholar
  18. Grant EC (2001) Systemic lupus erythematosus. Lancet 358:586CrossRefGoogle Scholar
  19. Gu Z, Cao X, Jiang J, Li L, Da Z, Liu H, Cheng C (2012a) Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal 24:2307–2314CrossRefGoogle Scholar
  20. Gu F, Molano I, Ruiz P, Sun L, Gilkeson GS (2012b) Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clin Immunol 145:142–152CrossRefGoogle Scholar
  21. Harizi H, Gualde N (2006) Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 3:271–277PubMedGoogle Scholar
  22. Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 9:12CrossRefGoogle Scholar
  23. Huck S, Le Corre R, Youinou P, Zouali M (2001) Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33:213–224CrossRefGoogle Scholar
  24. Laranjeira P, Gomes J, Pedreiro S, Pedrosa M, Martinho A, Antunes B, Ribeiro T, Santos F, Domingues R, Abecasis M, Trindade H, Paiva A (2015) Human bone marrow-derived mesenchymal stromal cells differentially inhibit cytokine production by peripheral blood monocytes subpopulations and myeloid dendritic cells. Stem Cells Int 2015:819084CrossRefGoogle Scholar
  25. Li K, Han Q, Yan X, Liao L, Zhao RC (2010) Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev 19:1267–1275CrossRefGoogle Scholar
  26. Liao J, Chang C, Wu H, Lu Q (2015) Cell-based therapies for systemic lupus erythematosus. Autoimmun Rev 14:43–48CrossRefGoogle Scholar
  27. Luu NT, McGettrick HM, Buckley CD, Newsome PN, Rainger GE, Frampton J, Nash GB (2013) Crosstalk between mesenchymal stem cells and endothelial cells leads to downregulation of cytokine-induced leukocyte recruitment. Stem Cells 31:2690–2702CrossRefGoogle Scholar
  28. Mandik-Nayak L, Ridge N, Fields M, Park AY, Erikson J (2008) Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol 20:639–645CrossRefGoogle Scholar
  29. Marino E, Grey ST (2012) B cells as effectors and regulators of autoimmunity. Autoimmunity 45:377–387CrossRefGoogle Scholar
  30. Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Front Biosci 13:453–461CrossRefGoogle Scholar
  31. Melief SM, Geutskens SB, Fibbe WE, Roelofs H (2013) Multipotent stromal cells skew monocytes towards an anti-inflammatory function: the link with key immunoregulatory molecules. Haematologica 98:e121–e122CrossRefGoogle Scholar
  32. Munir H, McGettrick HM (2015) Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells Dev 24:2091–2100CrossRefGoogle Scholar
  33. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20CrossRefGoogle Scholar
  34. Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L (2016) Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy 18:160–171CrossRefGoogle Scholar
  35. Pal R, Hanwate M, Jan M, Totey S (2009) Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med 3:163–174CrossRefGoogle Scholar
  36. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939CrossRefGoogle Scholar
  37. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141–150CrossRefGoogle Scholar
  38. Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P (2004) Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 3:516–523CrossRefGoogle Scholar
  39. Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, Cascioli S, Rossi F, Guzzo I, Vivarelli M, Dello Strologo L, Emma F, Locatelli F, Carsetti R (2015) Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 24:93–103CrossRefGoogle Scholar
  40. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197:777–788CrossRefGoogle Scholar
  41. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P (2010) Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 12:R31CrossRefGoogle Scholar
  42. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, Xu C, Chen X, Huang Y, Zhu Z, Huang X, Han X, Xie N, Ren G (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20:510–518CrossRefGoogle Scholar
  43. Spaggiari GM, Moretta L (2013) Interactions between mesenchymal stem cells and dendritic cells. Adv Biochem Eng Biotechnol 130:199–208PubMedGoogle Scholar
  44. Stock P, Bruckner S, Ebensing S, Hempel M, Dollinger MM, Christ B (2010) The generation of hepatocytes from mesenchymal stem cells and engraftment into murine liver. Nat Protoc 5:617–627CrossRefGoogle Scholar
  45. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121–128CrossRefGoogle Scholar
  46. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S (2009) Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27:1421–1432CrossRefGoogle Scholar
  47. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62:2467–2475CrossRefGoogle Scholar
  48. Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, Lu L, Zeng X, Sun L (2012) Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol 2012:826182CrossRefGoogle Scholar
  49. Tang Y, Xie H, Chen J, Geng L, Chen H, Li X, Hou Y, Lu L, Shi S, Zeng X, Sun L (2013) Activated NF-kappaB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. Stem Cells Dev 22:668–678CrossRefGoogle Scholar
  50. Tao JH, Cheng M, Tang JP, Liu Q, Pan F, Li XP (2017) Foxp3, regulatory T cell, and autoimmune diseases. Inflammation 40:328–339CrossRefGoogle Scholar
  51. Uccelli A, Moretta L, Pistoia V (2006) Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36:2566–2573CrossRefGoogle Scholar
  52. Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L (2014a) Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 16:R79CrossRefGoogle Scholar
  53. Wang H, Qi F, Dai X, Tian W, Liu T, Han H, Zhang B, Li H, Zhang Z, Du C (2014b) Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol 31:65–74CrossRefGoogle Scholar
  54. Wang D, Wang S, Huang S, Zhang Z, Yuan X, Feng X, Lu L, Sun L (2017) Serum IFN-gamma predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients. Stem Cells Transl Med 6:1777–1785CrossRefGoogle Scholar
  55. Williams JA, Pontzer CH, Shacter E (2000) Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J Interf Cytokine Res 20:291–298CrossRefGoogle Scholar
  56. Xiong W, Lahita RG (2014) Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10:97–107CrossRefGoogle Scholar
  57. Yang X, Yang J, Li X, Ma W, Zou H (2018) Bone marrow-derived mesenchymal stem cells inhibit T follicular helper cell in lupus-prone mice. Lupus 27(1):49–59. Scholar
  58. Youd M, Blickarz C, Woodworth L, Touzjian T, Edling A, Tedstone J, Ruzek M, Tubo R, Kaplan J, Lodie T (2010) Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 161:176–186PubMedPubMedCentralGoogle Scholar
  59. Zhang Y, Xia Y, Ni S, Gu Z, Liu H (2014) Transplantation of umbilical cord mesenchymal stem cells alleviates pneumonitis of MRL/lpr mice. J Thorac Dis 6:109–117PubMedPubMedCentralGoogle Scholar
  60. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L (2008) Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5:417–424CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Institute of Immunology, Zhejiang University School of MedicineHangzhouChina
  2. 2.Zhejiang University–University of Edinburgh Institute, Zhejiang University School of MedicineHangzhouChina
  3. 3.Veritas Genetics Asia Inc.HangzhouChina

Personalised recommendations